MC

725.6

+2.13%↑

ALV

266.9

+1.14%↑

SAF

204.5

+0.29%↑

BBVA

9.786

+0.72%↑

BN

59.08

+0.65%↑

MC

725.6

+2.13%↑

ALV

266.9

+1.14%↑

SAF

204.5

+0.29%↑

BBVA

9.786

+0.72%↑

BN

59.08

+0.65%↑

MC

725.6

+2.13%↑

ALV

266.9

+1.14%↑

SAF

204.5

+0.29%↑

BBVA

9.786

+0.72%↑

BN

59.08

+0.65%↑

MC

725.6

+2.13%↑

ALV

266.9

+1.14%↑

SAF

204.5

+0.29%↑

BBVA

9.786

+0.72%↑

BN

59.08

+0.65%↑

MC

725.6

+2.13%↑

ALV

266.9

+1.14%↑

SAF

204.5

+0.29%↑

BBVA

9.786

+0.72%↑

BN

59.08

+0.65%↑

Bayer AG

Затворен

Сектор Финансови

26.9 0.98

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

26.47

Максимум

27.045

Ключови измерители

By Trading Economics

Приходи

663M

2B

Продажби

1.9B

14B

EPS

2.82

Марж на печалбата

14.524

EBITDA

1.3B

4.4B

Препоръки

By TipRanks

Препоръки

Неутрален

12-месечна прогноза

+14.11 upside

Дивиденти

By Dow Jones

Следващи печалби

6.08.2024 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

-479M

25B

Предишно отваряне

25.92

Предишно затваряне

26.9

Настроения в новините

By Acuity

26%

74%

51 / 458 Класиране в Finance

Техническа оценка

By Trading Central

Увереност

Very Strong Bullish Evidence

Bayer AG Графика

Свързани новини

14.05.2024 г., 13:21 ч. UTC

Печалби

Bayer Plans More Job Cuts in Push for Fewer Bosses -- Update

14.05.2024 г., 06:13 ч. UTC

Печалби

Bayer Net Profit Falls on Lower Sales, Currency Headwinds

2.05.2024 г., 11:10 ч. UTC

Значими двигатели на пазара

Bayer Shares Surge After Monsanto Appeal Win

5.03.2024 г., 09:09 ч. UTC

Печалби
Придобивния, сливания и поглъщания

Bayer Decides Against Splitting Into Separate Units for Now -- 2nd Update

5.06.2024 г., 09:57 ч. UTC

Горещи акции

Stocks to Watch Wednesday: CrowdStrike, HPE, Dollar Tree -- WSJ

14.05.2024 г., 11:00 ч. UTC

Пазарно говорене
Печалби

Bayer Earnings Show Progression on Turnaround Strategy -- Market Talk

14.05.2024 г., 05:34 ч. UTC

Печалби

Bayer Backs 2024 Currency-Adjusted Outlook

14.05.2024 г., 05:32 ч. UTC

Печалби

Bayer: Analysts Saw 1Q Ebitda Before Special Items at EUR4.15B

14.05.2024 г., 05:32 ч. UTC

Печалби

Bayer 1Q Ebitda Before Special Items EUR4.41B

14.05.2024 г., 05:32 ч. UTC

Печалби

Bayer 1Q EPS EUR2.04

14.05.2024 г., 05:32 ч. UTC

Печалби

Bayer: Analysts Saw 1Q Sales at EUR14.08B

14.05.2024 г., 05:32 ч. UTC

Печалби

Bayer 1Q Sales EUR13.77B

14.05.2024 г., 05:31 ч. UTC

Печалби

Bayer 1Q EBIT EUR3.09B

14.05.2024 г., 05:31 ч. UTC

Печалби

Bayer: Analysts Saw 1Q Net Pft at EUR1.73B

14.05.2024 г., 05:31 ч. UTC

Печалби

Bayer 1Q Net Pft EUR2B

13.05.2024 г., 13:26 ч. UTC

Печалби

Bayer Investors Brace for Long Turnaround -- Talking Markets

15.04.2024 г., 14:01 ч. UTC

Пазарно говорене
Придобивния, сливания и поглъщания

Bayer's Consumer-Healthcare Unit Remains Attractive Acquisition Target -- Market Talk

15.04.2024 г., 13:39 ч. UTC

Пазарно говорене

Bayer's Debt Reduction, Litigation and Drug Pipeline in Focus at 1Q Results -- Market Talk

22.03.2024 г., 04:01 ч. UTC

Топ новини

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ -2-

22.03.2024 г., 04:01 ч. UTC

Топ новини

One CEO's Radical Fix for Corporate Troubles: Purge the Bosses -- WSJ

5.03.2024 г., 10:23 ч. UTC

Печалби

Bayer CEO Was Speaking on Call After Earnings

5.03.2024 г., 10:19 ч. UTC

Пазарно говорене
Печалби

Bayer's EPS Guidance Implies Consensus Downgrades -- Market Talk

5.03.2024 г., 09:55 ч. UTC

Пазарно говорене
Печалби

Bayer's 2024 Guidance Is Below Expectations -- Market Talk

5.03.2024 г., 09:44 ч. UTC

Печалби

Bayer CEO: Time it Takes For Major Structural Change is Time We Don't Have, Need to Focus on Challenges

5.03.2024 г., 09:44 ч. UTC

Печалби

Bayer CEO: There Has Been Calls From Major Shareholders For Break-Up, But They Understand Associated Drawbacks

5.03.2024 г., 08:52 ч. UTC

Печалби

Bayer CEO: Exploring All Avenues to Remove Litigation Completely

5.03.2024 г., 08:51 ч. UTC

Печалби

Bayer CEO: Strategy of Defence Against Litigation is Not Enough

5.03.2024 г., 08:44 ч. UTC

Печалби

Bayer CEO: Need Total Focus on Overcoming Challenges

5.03.2024 г., 08:44 ч. UTC

Печалби

Bayer CEO: Separation of Consumer Health Would Remove Steady Cash Flowing Business, Valutions Not Great

5.03.2024 г., 08:43 ч. UTC

Печалби

Bayer CEO: IPO or Spin Would Require All-Hands on Deck For Long Period

Сравнение с други в отрасъла

Ценова промяна

Bayer AG Прогноза

Ценова цел

By TipRanks

14.11% нагоре

12-месечна прогноза

Среден 30.4 EUR  14.11%

Висок 34 EUR

Нисък 28 EUR

Според 12 анализатори от Wall Street, предложили 12-месечна ценова цел за Bayer AG през последните три месеца.

Консенсусна оценка

By TipRanks

Неутрален

12 ratings

1

Купи

11

Задържане

0

Продай

Техническа оценка

By Trading Central

26.11 / 26.64Подкрепа & съпротива

Краткосрочен план

Very Strong Bullish Evidence

Средносрочен план

Weak Bearish Evidence

Дългосрочен план

Weak Bearish Evidence

Настроение

By Acuity

51 / 458 Класиране в Финансови

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

EBITDA

Оперативна печалба

$

Относно Bayer AG

Bayer AG is a German-based life science company. The Company's segments are Pharmaceuticals, Consumer Health, Crop Science and Animal Health. The Pharmaceuticals segment focuses on researching, developing and marketing prescription products and specialty therapeutics especially in the areas of cardiology, oncology, gynecology, hematology and ophthalmology, as well as radiopharmacology and others. The company is focusing on their oncology platform o Targeted Alpha Therapies for treating prostate cancer. Th Consumer Health segment develops, produces and markets nonprescription over-the-counter products in the dermatology, dietary supplement, analgesic, gastrointestinal, cold, allergy, sinus and flu, foot care and sun protection categories, among others. The Crop Science segment researches, develops and markets crop protection solutions and seeds, and includes the subsidiary Monsanto. The Animal Health segment is engaged in the development, production and marketing of prescription and non